MUNICH—Wacker Biosolutions, one of four business units within Wacker Chemie A.G., is making a change in the C-suite, as Mathias Wiedemann will take over as president for Susanne Leonhartsberger.
The succession is effective Jan. 1, 2025.
"I am delighted that we have been able to recruit Mathias Wiedemann, an outstanding colleague from our own midst, to head our biotech division," said Wacker CEO Christian Hartel. "I wish him every success in his new role."
Leonhartsberger is leaving at her own request, after leading the biosolutions division since 2020. She joined Wacker in 2001, leaving a legacy of milestones.
One of her biggest accomplishments was establishing an mRNA competence center in Halle/Saale, Germany, and subsequent pandemic-preparedness agreements with the German government.
"Susanne Leonhartsberger has taken biosolutions a decisive step forward on its growth path," Hartel said. "On behalf of the entire executive board, I would like to thank her for her commitment and dedication. We wish her all the best for the future."